Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies
Patients not eligible for any biologic treatments were characterized by the highest FeNO (33.2 ppb, P < 0.001), with raised sputum eosinophils and BEC (270/μL) and none received OCS therapy. Because the UK National Health and Care Institute has advocated the use of these biologics using different...
Saved in:
Published in | Chinese medical journal Vol. 136; no. 2; pp. 230 - 232 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
China
Lippincott Williams & Wilkins Ovid Technologies
20.01.2023
Lippincott Williams & Wilkins Wolters Kluwer |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!